Understanding why some people with hemophilia develop harmful antibodies to replacement therapies
Official title: Alloimmune responses to hemophilia therapeutics
Funded at Emory University · NIH-11309332 · Data updated 2026-11-12
Researchers are studying why some patients with hemophilia develop immune antibodies that block factor therapies and cause problems, with a focus on predicting who might be affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $391,211 |
| NIH project number | 1R00HL184325-01 |
| Project ID | NIH-11309332 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with hemophilia A or B who are treated with factor replacement therapies and may develop or already have inhibitors.
✕Less likely to help
Patients not undergoing factor replacement therapy or without immune-related responses to these therapies may have limited direct benefit.
What this research studies
This project looks at how the body’s immune system reacts to coagulation factor replacements like FVIII and FIX. It aims to identify early markers of immune responses that lead to inhibitors and to understand why immune tolerance therapies sometimes fail. The work combines biological analysis with clinical insights to improve how we predict and manage adverse immune reactions in patients who rely on factor therapies. If successful, it could guide personalized approaches to prevent or mitigate inhibitor development.
Why it matters
Potential benefit: It could lead to better prediction and prevention of inhibitor formation, improving effectiveness of life-saving therapies for people with hemophilia.
How similar studies have gone: Previous studies have linked immune markers to inhibitor development, but precise predictors and early markers remain an area of active exploration.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Doshi, Bhavya Sharad — Emory University
- Study coordinator: Doshi, Bhavya Sharad
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
Enhancing immune regulation in gene therapy for hemophilia (new approaches to safer treatment)
A patient-focused overview of a long-running NIH grant exploring how to make gene therapy for hemophilia safer by teaching the body’s immune system to tolerate the therapeutic protein.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Non-viral gene therapy approach to permanently fix hemophilia B
A new gene therapy approach aims to permanently correct hemophilia B without using viruses, potentially reducing bleeding events for people with this condition.
-
Hemophilia Point-of-Care Test Gets Regulatory Ready
A new point-of-care test for hemophilia A measures FVIII and emicizumab to help doctors manage bleeding risk quickly, with plans to obtain regulatory clearance.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.